New research perspectives were published in Volume 13. oncology science Published on March 11, 2026, entitled “Early success of the COCOON trial: Prevention of dermatological adverse events in first-line EGFR-mutant NSCLC.”
This commentary, led by lead and corresponding author Vishal Tiwari of Nassau University Medical Center and Asmita Koirala of Western Nepal Regional Hospital, summarizes interim results from the phase II COCOON trial, which tested whether a structured dermatological prophylaxis regimen could reduce skin toxicity in patients receiving first-line amivantamab and lazertinib combinations.
This commentary describes a prophylactic protocol that includes oral doxycycline or minocycline, ceramide-based moisturizers, chlorhexidine nail care, and topical clindamycin. In the interim analysis, the COCOON regimen reduced moderate-to-severe dermatological adverse events, reducing the rate of grade 2 or higher events from 76.5% with standard reactive therapy to 38.6% with preventive therapy. This paper also reports a reduction in grade 3 or higher events and treatment discontinuation, highlighting the practical value of aggressive supportive care for EGFR-mutant non-small cell lung cancer.
“COCOON results highlight the clinical value of predicting EGFR inhibitor-related toxicity through multidisciplinary supportive care.”
The authors conclude that these results reinforce the need to incorporate dermatological prophylaxis into first-line treatment regimens for EGFR-mutant NSCLC. They point out that while direct, low-cost interventions can improve tolerability and maintain dose intensity, future clinical practice updates are likely to more broadly incorporate this type of aggressive supportive care approach.
sauce:
Reference magazines:
Tiwari, B., Koirala, A. (2026). Early success of the COCOON trial: Prevention of dermatological adverse events in first-line EGFR-mutated NSCLC. Oncology science. DOI: 10.18632/oncoscience.648. https://www.oncoscience.us/article/648/text/
